USD
+$0.00
(+0.00%
)At Close (As of Sep 26, 2025)
$1.92B
Market Cap
-
P/E Ratio
-0.68
EPS
$138.81
52 Week High
$10.41
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $1.6B |
Total Revenue | $1.9B |
Cost Of Revenue | $319M |
Costof Goods And Services Sold | $319M |
Operating Income | $218M |
Selling General And Administrative | $558M |
Research And Development | $805M |
Operating Expenses | $1.4B |
Investment Income Net | - |
Net Interest Income | $53M |
Interest Income | $72M |
Interest Expense | $18M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $54M |
Income Before Tax | $261M |
Income Tax Expense | $26M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $235M |
Comprehensive Income Net Of Tax | - |
Ebit | $279M |
Ebitda | $333M |
Net Income | $235M |
Field | Value (USD) |
---|---|
Total Assets | $4B |
Total Current Assets | $3.1B |
Cash And Cash Equivalents At Carrying Value | $1.1B |
Cash And Short Term Investments | $1.1B |
Inventory | $750M |
Current Net Receivables | $650M |
Total Non Current Assets | $890M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $27M |
Intangible Assets Excluding Goodwill | $27M |
Goodwill | - |
Investments | - |
Long Term Investments | $137M |
Short Term Investments | $252M |
Other Current Assets | $319M |
Other Non Current Assets | - |
Total Liabilities | $2.4B |
Total Current Liabilities | $732M |
Current Accounts Payable | $214M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $13M |
Total Non Current Liabilities | $1.7B |
Capital Lease Obligations | $206M |
Long Term Debt | $1.1B |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $1.3B |
Other Current Liabilities | $370M |
Other Non Current Liabilities | $49M |
Total Shareholder Equity | $1.5B |
Treasury Stock | - |
Retained Earnings | -$4.2B |
Common Stock | $10K |
Common Stock Shares Outstanding | $108M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$206M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $38M |
Capital Expenditures | $137M |
Change In Receivables | - |
Change In Inventory | -$395M |
Profit Loss | - |
Cashflow From Investment | $756M |
Cashflow From Financing | $125M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $235M |
Field | Value (USD) |
---|---|
Gross Profit | $1.6B |
Total Revenue | $1.9B |
Cost Of Revenue | $319M |
Costof Goods And Services Sold | $319M |
Operating Income | $218M |
Selling General And Administrative | $558M |
Research And Development | $805M |
Operating Expenses | $1.4B |
Investment Income Net | - |
Net Interest Income | $53M |
Interest Income | $72M |
Interest Expense | $18M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $54M |
Income Before Tax | $261M |
Income Tax Expense | $26M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $235M |
Comprehensive Income Net Of Tax | - |
Ebit | $279M |
Ebitda | $333M |
Net Income | $235M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Sarepta Therapeutics, Inc. is a leading biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the development of innovative RNA-targeted therapies and gene therapies for rare genetic disorders. With a robust pipeline and a commitment to addressing unmet medical needs, Sarepta is at the forefront of transforming treatment paradigms for conditions such as Duchenne muscular dystrophy (DMD). The company leverages cutting-edge science and technology to create novel therapeutics, positioning itself as a key player in the evolving landscape of genetic medicine.